St. John’s wort and its component hyperforin alleviate experimental autoimmune encephalomyelitis through expansion of regulatory T-cells

Journal of Immunotoxicology

Volumn 13, Issue 3, 2016, Pages 364-374

  Nosratabadi, Reza ^a,b   Rastin, Maryam ^a   Sankian, Mojtaba ^a   Haghmorad, Dariush ^a   Tabasi, Nafiseh ^a   Zamani, Shahrzad ^a   Aghaee, Azita ^c   Salehipour, Zohre ^a   Mahmoudi, Mahmoud ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Experimental autoimmune encephalomyelitis (EAE); hyperforin; Hypericum perforatum L; multiple sclerosis; myelin oligodendrocyte glycoprotein (MOG)

Indexed keywords

HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55); PEPTIDE FRAGMENT; PHLOROGLUCINOL; TERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CELL EXPANSION; DRUG EFFICACY; DRUG SYNTHESIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; IMMUNIZATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPINAL CORD; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; DISEASE MODEL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMAN; HYPERICUM; IMMUNOLOGY; PHYTOTHERAPY; SPLEEN;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; HYPERICUM; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; PEPTIDE FRAGMENTS; PHLOROGLUCINOL; PHYTOTHERAPY; SPLEEN; T-LYMPHOCYTES, REGULATORY; TERPENES;

EID: 84949233686     PISSN: 1547691X     EISSN: 15476901     Source Type: Journal    
DOI: 10.3109/1547691X.2015.1101512     Document Type: Article

References (31)

1. J.Barnes, L.A.Anderson, J.D.Phillipson. 2001. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 53:583–600.
2. L.J.Barten, D.R.Allington, K.A.Procacci, M.P.Rivey. 2010. New approaches in the management of multiple sclerosis. Drug Design Devel Ther. 4:343.
3. H.Batoulis, K.Addicks, S.Kuerten. 2010. Emerging concepts in autoimmune encephalomyelitis beyond the CD4/T H 1 paradigm. Ann Anat-Anatom Anzeiger. 192:179–193.
4. S.Bhattacharya, A.Chakrabarti, S.Chatterjee. 1998. Activity profiles of two hyperforin-containing hypericum extracts in behavioral models. Pharmacopsychiatry. 31:22–29.
5. B.J.Bray, N.J.Brennan, N.B.Perry, D.Menkes, R.Rosengren. 2002. Short-term treatment with St. John's wort, hypericin or hyperforin fails to induce CYP450 isoforms in Swiss Webster mouse. Life Sci. 70:1325–1335.
6. W.Brück. 2005. Pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neuro. 252:v3–v9.
7. H1-triggered CNS inflammatory-demyelinating disease. J Leukocyte Biol. 83:212–219.
8. E.Corsini, M.Oukka, R.Pieters, N.I.Kerkvliet, R.Ponce, D.R.Germolec. 2011. Alterations in regulatory T-cells: Re-discovered pathways in immunotoxicology. J Immunotoxicol. 8:251–257.
9. M.Cristofanilli, H.Rosenthal, B.Cymring, D.Gratch, B.Pagano, B.Xie, S.A.Sadiq. 2014. Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice. Exp Neurol. 261:620–632.
10. I.Dell’aica, R.Niero, F.Piazza, A.Cabrelle, L.Sartor, C.Colalto, E.Brunetta, G.Lorusso, R.Benelli, A.Albini. 2007. Hyperforin blocks neutrophil activation of matrix metalloproteinase-9, motility and recruitment, and restrains inflammation-triggered angio-genesis and lung fibrosis. J Pharmacol Exp Ther. 321:492–500.
11. + T-cells in brain lesions and cerebrospinal fluid of multiple sclerosis patients. PLoS One. 6:e17988.
12. J.Gibon, J.C.Deloulme, T.Chevallier, E.Ladeveze, D.N.Abrous, A.Bouron. 2013. The anti-depressant hyperforin increases the phosphorylation of CREB and expression of TrkB in a tissue-specific manner. Intl J Neuropsychopharmacol. 16:189–198.
13. M.Gomez Del Rio, M.Sánchez-Reus, I.Iglesias, M.Pozo, M.Garcia-Arencibia, J.Fernandez-Ruiz, L.García-García, M.Delgado, J.Benedí. 2013. Neuroprotective properties of standardized extracts of Hypericum perforatum on rotenone model of Parkinson’s disease. CNS Neurol Disorders. 12:665–679.
14. H2 cells. J Neuroimmunol. 277:85–95.
15. B.Hemmer, S.Nessler, D.Zhou, B.Kieseier, H.-P.Hartung. 2006. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Practice Neurol. 2:201–211.
16. N.Kawakami, I.Bartholomäus, M.Pesic, M.Mues. 2012. An autoimmunity odyssey: How autoreactive T-cells infiltrate into the CNS. Immunol Rev. 248:140–155.
17. reg cells mediate recovery from EAE by controlling effector T-cell proliferation and motility in the CNS. Acta Neuropathol Commun. 2:163.
18. B.Kraus, H.Wolff, J.Heilmann, E.F.Elstner. 2007. Influence of Hypericum perforatum extract and its single compounds on amyloid-β-mediated toxicity in microglial cells. Life Sci. 81:884–894.
19. K.Markoullis, I.Sargiannidou, C.Gardner, A.Hadjisavvas, R.Reynolds, K.A.Kleopa. 2012. Disruption of oligodendrocyte gap junctions in experimental autoimmune encephalo-myelitis. Glia. 60:1053–1066.
20. M.C.Meinke, S.Schanzer, S.F.Haag, F.Casetti, M.L.Müller, U.Wölfle, A.Kleemann, J.Lademann, C.M.Schempp. 2012. In vivo photoprotective and anti-inflammatory effect of hyperforin is associated with high anti-oxidant activity in vitro and ex vivo. Eur J Pharm Biopharm. 81:346–350.
21. E.Mix, H.Meyer-Rienecker, H.P.Hartung, U.K.Zettl. 2010. Animal models of multiple sclerosis – potentials and limitations. Prog Neurobiol. 92:386–404.
22. M.Mohanasundari, M.Sabesan. 2007. extract on astrocytes in MPTP induced Parkinson’s disease in mice. Eur Rev Med Pharmacolog Sci. 11:17–20.
23. S.Mondal, K.Pahan. 2015. Cinnamon ameliorates experimental allergic encephalomyelitis in mice via regulatory T-cells: Implications for Multiple Sclerosis therapy. PLoS One 10:e0116566.
24. B.Moreno, H.Hevia, M.Santamaria, J.Sepulcre, J.Muñoz, García-E.R.Trevijano, C.Berasain, F.J.Corrales, M.A.Avila, P.Villoslada. 2006. Methylthioadenosine reverses brain auto-immune disease. Ann Neurol. 60:323–334.
25. S.Mozaffari, H.Esmaily, R.Rahimi, M.Baeeri, Y.Sanei, A.Asadi-Shahmirzadi, M.-H.Salehi-Surmaghi, M.Abdollahi. 2011. Effects of Hypericum perforatum extract on rat irritable bowel syndrome. Pharmacog Mag. 7:213.
26. + natural regulatory T-cells in dominant self‐tolerance and autoimmune disease. Immunol Rev. 212:8–27.
27. C.Schneider, G.Schuetz, T.M.Zollner. 2009. Acute neuroinflammation in Lewis rats: A model for acute multiple sclerosis relapses. J Neuroimmunol. 213:84–90.
28. I.A.Soellner, J.Rabe, V.Mauri, J.Kaufmann, K.Addicks, S.Kuerten. 2013. Differential aspects of immune cell infiltration and neurodegeneration in acute and relapse experimental autoimmune encephalomyelitis. Clin Immunol. 149:519–529.
29. C.Stadelmann, C.Wegner, W.Brück. 2011. Inflammation, demyelination, and degeneration – recent insights from MS pathology. Biochim Biophys Acta. 1812:275–282.
30. I.P.Süntar, E.K.Akkol, D.Yılmazer, T.Baykal, H.Kirmizibekmez, M.Alper, E.Yesilada. 2010. Investigations on the in vivo wound healing potential of Hypericum perforatum L. J Ethnopharmacol. 127:468–477.
31. U.Wolfle, G.Seelinger, C.M.Schempp. 2014. Topical application of St. John's wort (Hypericum perforatum). Planta Med. 80:109–120.